D. E. Shaw & Co., Inc. I Teos Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 219,323 shares of ITOS stock, worth $2.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

219,323

Previous 136,720 60.42%

Holding current value

$2.19 Million

Previous $1.86 Million 74.57%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.33 - $18.09 $853,288 - $1.49 Million	82,603 Added 60.42%	219,323 $3.25 Million
Q1 2024 May 15, 2024	SELL	$9.89 - $13.64 $250,592 - $345,610	-25,338 Reduced 15.64%	136,720 $1.86 Million
Q4 2023 Feb 14, 2024	BUY	$8.57 - $11.06 $407,932 - $526,456	47,600 Added 41.59%	162,058 $1.77 Million
Q3 2023 Nov 14, 2023	BUY	$10.95 - $14.6 $382,987 - $510,649	34,976 Added 44.0%	114,458 $1.25 Million
Q2 2023 Aug 14, 2023	BUY	$12.93 - $18.05 $88,130 - $123,028	6,816 Added 9.38%	79,482 $1.05 Million
Q1 2023 May 15, 2023	BUY	$13.02 - $22.62 $73,602 - $127,870	5,653 Added 8.44%	72,666 $988,000
Q4 2022 Feb 14, 2023	SELL	$17.77 - $21.6 $332,867 - $404,611	-18,732 Reduced 21.85%	67,013 $1.31 Million
Q3 2022 Nov 14, 2022	BUY	$18.6 - $27.25 $962,345 - $1.41 Million	51,739 Added 152.15%	85,745 $1.63 Million
Q2 2022 Aug 15, 2022	BUY	$16.57 - $35.1 $563,479 - $1.19 Million	34,006 New	34,006 $701,000
Q2 2021 Aug 16, 2021	SELL	$17.9 - $36.1 $138,581 - $279,486	-7,742 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$30.86 - $44.2 $54,282 - $77,747	1,759 Added 29.4%	7,742 $265,000
Q4 2020 Feb 16, 2021	BUY	$21.59 - $33.95 $129,172 - $203,122	5,983 New	5,983 $202,000

Others Institutions Holding ITOS

# of Institutions

149

Shares Held

36.3M

Call Options Held

653K

Put Options Held

1.48M

View Full List

About iTeos Therapeutics, Inc.

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $356M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

More about ITOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account